Area:
Clinical Psychology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Katherine L. Schaefer is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2004 — 2006 |
Schaefer, Katherine L |
F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Non-Classical Effects of Tzds On Chemokine Produciton
DESCRIPTION (provided by applicant): Inflammatory bowel diseases (IBD) are characterized by episodes of intestinal inflammation. Recent evidence suggests that activation of a nuclear receptor, PPAR-gamma, with a synthetic TZD ligand, BRL, offers protection against inflammation, at least in part by regulating inflammatory chemokine production from intestinal epithelial cells, both at the transcriptional and post-transcriptional levels. Interestingly, the chemokine promoters do not have PPAR-gamma response elements, indicating that the activated PPAR-gamma, or possibly BRL itself, affect chemokine production in "non-classical" ways. In addition, BRL affects numerous rapid phosphorylation events after cellular stimulation, including many molecules involved in MAP kinase signaling. To test the hypothesis that activated PPAR-gamma or BRL itself regulate chemokine production by modulating MAP kinase signaling, the mechanisms of regulation of a representative chemokine, IP-10, will be determined. The effects of BRL on IP-10 regulation in the presence and absence of PPAR-gamma will be determined, and the signaling pathways affected by BRL delineated in detail. The results of these experiments will further understanding of the mechanism of action of synthetic PPAR-gamma ligands and help in the development of IBD therapies.
|
0.942 |